• Clarified exclusion criteria number 10 stating exclusion of patients with known hypersensitivity to taxanes. • Added clarification that worsening of bone pain requiring palliative radiation therapy will be considered clinical disease progression. • Corrected the permissible time window for hematology and serum biochemistry assesments on day 1 of each cycle to be consistent with other sections of the protocol. • Changed the dose modification relating to hematology toxicity to state that custirsen will not be held or modified. • Corrected the pharmacokinetic sampling procedure.

• Added new exclusion criterion stating that patients with known and documented epidermal growth factor (EGFR) mutation who have not received an EGFR inhibitor must be excluded. • Revised pregnancy precautions for men of reproductive potential to use precautionary instruction as outlined in the docetaxel summary of product characteristics. • Revised diluents acceptable for custirsen formulation to include either 0.9% normal saline or 0.9% D5W. • Changed sample type for pregnancy testing (beta-human chorionic gonadotropin) for female subjects of childbearing potential from urine to serum. • Clarified terms for relationship of an adverse event to study drug by adding (not related) to No reasonable possibility and adding (related) to Reasonable possibility.

• Changed sponsorship of study from Teva Pharmaceutical Industries, Ltd. to OncoGenex Technologies Inc. • Clarified 3 week delay in treatment timing for patient withdrawal. • Clarified that radiation therapy specifically for lung cancer could be reason for patient withdrawal. • Clarified Day 1 of each cycle is tied the day of docetaxel administration. • Clarified that a subject should have an “End of Treatment” assessment if more than 42 days between docetaxel administrations. • Clarified that either docetaxel or custirsen should be modified or held based on hematology toxicity for dose modification guidelines as outlined in protocol. • Changed SGOT (AST) Grade 1 and Grade 2 levels for dose modifications for hepatic toxicity (Grade 1 changed from <2.5x upper limit of normal [ULN] to <3.0xULN and Grade 2 from >2.5xULN to >3.0xULN). • Clarified that study period for serious adverse event reporting is from the subject’s signature on the informed consent form until the end of the treatment visit (28 days following last dose). • Changed parameters based on revision of the primary objective hypothesized HR from 0.8 to 0.75 as follows: 850 death events to 508 death events required, recruitment period of 4 years to 3.1 years and sample size target of 1100 to 700. • Added that OS analysis will include comparison by histology (squamous, non-squamous) between subjects receiving docetaxel with or without custirsen.

• Decreased the number of subjects to be enrolled from 700 to approximately 660 and referenced the revised Statistical Analysis Plan (Version 3.1) which covered details related to patient enrollment and target of 447 death events for final analysis.